skip to Main Content

Maverick Therapeutics Drives Innovation In Cancer Immuno-oncology

Maverick Therapeutics is pioneering the next generation of redirected T-cell targeted immunotherapies. Maverick’s highly innovative platform, COBRA™, is the most advanced bispecific T-cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity. Maverick was founded in 2016 by a team of leading experts in protein engineering and T-cell therapeutic research and development. In early 2017, Maverick announced $125 million of committed funding from Takeda Pharmaceuticals (“Takeda”), MPM BioVentures 2014 and MPM Capital’s UBS Oncology Impact Fund. Based on the promise of the Company’s early-stage research, Maverick entered a five-year drug development project with Takeda.


Maverick Therapeutics is a place where passionate innovators, dedicated achievers and team players thrive personally and professionally. We strive to succeed wildly and enjoy the journey.

Back To Top